Cargando…

PIK3CA in Colorectal Cancer

PIK3CA, the catalytic subunit of PI3K, is mutated in many different tumors, including colorectal cancer (CRC). Mutations of PIK3CA have been reported in 10–20% of CRC, about 80% of mutations found in two hot spots in exon 9 and exon 20. In RAS wild-type CRC, PIK3CA mutations have been associated wit...

Descripción completa

Detalles Bibliográficos
Autor principal: Cathomas, Gieri
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3939771/
https://www.ncbi.nlm.nih.gov/pubmed/24624362
http://dx.doi.org/10.3389/fonc.2014.00035
_version_ 1782305741523124224
author Cathomas, Gieri
author_facet Cathomas, Gieri
author_sort Cathomas, Gieri
collection PubMed
description PIK3CA, the catalytic subunit of PI3K, is mutated in many different tumors, including colorectal cancer (CRC). Mutations of PIK3CA have been reported in 10–20% of CRC, about 80% of mutations found in two hot spots in exon 9 and exon 20. In RAS wild-type CRC, PIK3CA mutations have been associated with a worse clinical outcome and with a negative prediction of a response to targeted therapy by anti-EGFR monoclonal antibodies. However, these findings have not been confirmed in all studies and subsequent more detailed analysis has revealed that these effects may be restricted to mutations in Exon 20. Finally, mutations in PIK3CA may be the long sought biomarker for successful adjuvant therapy with aspirin in patients with CRC. Therefore, PIK3CA mutations appear to be a promising predictive biomarker; however, further data are needed to conclusively define the impact of somatic mutations in the PIK3CA gene for the management of patients with CRC.
format Online
Article
Text
id pubmed-3939771
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-39397712014-03-12 PIK3CA in Colorectal Cancer Cathomas, Gieri Front Oncol Oncology PIK3CA, the catalytic subunit of PI3K, is mutated in many different tumors, including colorectal cancer (CRC). Mutations of PIK3CA have been reported in 10–20% of CRC, about 80% of mutations found in two hot spots in exon 9 and exon 20. In RAS wild-type CRC, PIK3CA mutations have been associated with a worse clinical outcome and with a negative prediction of a response to targeted therapy by anti-EGFR monoclonal antibodies. However, these findings have not been confirmed in all studies and subsequent more detailed analysis has revealed that these effects may be restricted to mutations in Exon 20. Finally, mutations in PIK3CA may be the long sought biomarker for successful adjuvant therapy with aspirin in patients with CRC. Therefore, PIK3CA mutations appear to be a promising predictive biomarker; however, further data are needed to conclusively define the impact of somatic mutations in the PIK3CA gene for the management of patients with CRC. Frontiers Media S.A. 2014-03-03 /pmc/articles/PMC3939771/ /pubmed/24624362 http://dx.doi.org/10.3389/fonc.2014.00035 Text en Copyright © 2014 Cathomas. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Cathomas, Gieri
PIK3CA in Colorectal Cancer
title PIK3CA in Colorectal Cancer
title_full PIK3CA in Colorectal Cancer
title_fullStr PIK3CA in Colorectal Cancer
title_full_unstemmed PIK3CA in Colorectal Cancer
title_short PIK3CA in Colorectal Cancer
title_sort pik3ca in colorectal cancer
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3939771/
https://www.ncbi.nlm.nih.gov/pubmed/24624362
http://dx.doi.org/10.3389/fonc.2014.00035
work_keys_str_mv AT cathomasgieri pik3caincolorectalcancer